TECENTRIQ® (Atezolizumab)

The FDA on October 18, 2016 approved TECENTRIQ® for the treatment of patients with metastatic Non Small Cell Lung Cancer (NSCLC) whose disease progressed during or following Platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations, prior to receiving TECENTRIQ®. TECENTRIQ® is a product of Genentech, Inc.